Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Boleros (Música)
6
Historia y crítica
6
Música orquestal
6
Música popular
6
Música para piano
4
Textos
4
Ballets
3
Música
3
Ballets (Música)
2
Civilización
2
Cultura popular
2
Historia
2
Música para guitarra
2
Novela cubana
2
Novela mexicana
2
Suites (Orchestra)
2
Suites (Orquesta)
2
Arreglos
1
Arte
1
Aspectos políticos
1
Aspectos sociales
1
Boleros
1
Boleros (Orchestra)
1
Boleros (piano)
1
Canciones
1
Castañuelas
1
Compositores
1
Corno (Instrumento musical)
1
Cri-crí
1
Crotalogía
1
-
21
-
22por Johnston, Stephen RDEnlace del recurso
Publicado 2012
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
23por Gupta, SudeepEnlace del recurso
Publicado 2014
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
24por Peza Casares, María del Carmen de laMaterias: “…Boleros (Música) México.…”
Publicado 2001
Libro -
25por Hortobagyi, Gabriel N.“…The mTOR inhibitor everolimus, in combination with exemestane, has been approved for patients with advanced hormone receptor–positive/HER2-negative breast cancer who progress on prior nonsteroidal aromatase inhibitor therapy based on results reported in the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) study. This review will summarize the overall findings from BOLERO-2 and will consider available subanalyses by age, Asian origin, visceral or bone metastases, and prior therapy, with the aim of identifying populations most likely to benefit from everolimus therapy. …”
Publicado 2015
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
26por Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine“…The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
27
-
28por Chopin, Frédéric, 1810-1849Tabla de Contenidos: “…24 preludes, op. 28 -- Prelude in A flat major -- Prelude, op. 45 -- Barcarolle, op. 60 -- Bolero, op. 19 -- Bourrée I -- Bourrée II -- Wiosna -- Feuille d'album -- Fugue.…”
Publicado 1992
CD Audiom -
29por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.“…Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
30por Toi, Masakazu, Shao, Zhimin, Hurvitz, Sara, Tseng, Ling-Ming, Zhang, Qingyuan, Shen, Kunwei, Liu, Donggeng, Feng, Jifeng, Xu, Binghe, Wang, Xiaojia, Lee, Keun Seok, Ng, Ting Ying, Ridolfi, Antonia, Noel-baron, Florence, Ringeisen, Francois, Jiang, Zefei“…BACKGROUND: The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in the BOLERO-1 trial. METHODS: Postmenopausal women with HER2+ advanced breast cancer, who had not received systemic therapy for advanced disease, were randomized 2:1 to receive everolimus or placebo, plus trastuzumab and paclitaxel. …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
31por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.Enlace del recurso
Publicado 2014
Enlace del recurso
Online Artículo Texto -
32por Noguchi, Shinzaburo, Masuda, Norikazu, Iwata, Hiroji, Mukai, Hirofumi, Horiguchi, Jun, Puttawibul, Puttisak, Srimuninnimit, Vichien, Tokuda, Yutaka, Kuroi, Katsumasa, Iwase, Hirotaka, Inaji, Hideo, Ohsumi, Shozo, Noh, Woo-Chul, Nakayama, Takahiro, Ohno, Shinji, Rai, Yoshiaki, Park, Byeong-Woo, Panneerselvam, Ashok, El-Hashimy, Mona, Taran, Tetiana, Sahmoud, Tarek, Ito, Yoshinori“…BACKGROUND: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR(+)) breast cancer refractory to letrozole or anastrozole. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
33por Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-Hashimy, M., Taran, T., Burris, H. A.“…BACKGROUND: In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
34
-
35
-
36por Moynahan, Mary Ellen, Chen, David, He, Wei, Sung, Patricia, Samoila, Aliaksandra, You, Daoqi, Bhatt, Trusha, Patel, Parul, Ringeisen, Francois, Hortobagyi, Gabriel N, Baselga, Jose, Chandarlapaty, Sarat“…BACKGROUND: The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at the time of patient randomisation. …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
37
-
38
-
39“…Qualitative studies have an important role to play in exploring reasons for low recruitment, although to date few such studies have been carried out that are embedded in surgical trials. The BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy) is a study to determine the feasibility of randomisation to open versus laparoscopic access/robotic cystectomy in patients with bladder cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
40